NCT02152982 2026-04-13
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
Clinical Trials
15 trialsNCT03970447 2026-04-08
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
NCT04396860 2026-03-05
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT06105619 2026-01-20
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Beijing Pearl Biotechnology Limited Liability Company
Phase 2/3 Active not recruiting
NCT07349693 2026-01-20
Cerebraca-02/3
Everfront Biotech Co., Ltd.
Phase 2/3 Not yet recruiting
NCT06624644 2025-09-10
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3 Recruiting
NCT01236560 2024-02-20
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT03008148 2021-05-11
Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM
Johnpro Biotech, Inc.
Phase 2/3 Unknown
NCT02678975 2021-03-18
Disulfiram in Recurrent Glioblastoma
Sahlgrenska University Hospital
Phase 2/3 Completed
NCT04105374 2020-03-24
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
NRG Oncology
Phase 2/3 Withdrawn
NCT02414165 2020-02-07
Toca5
Tocagen Inc.
Phase 2/3 Terminated
NCT04244708 2020-01-28
The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas
Peking Union Medical College Hospital
Phase 2/3 Unknown
NCT03732482 2019-01-29
Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases
Taizhou Hospital
Phase 2/3 Unknown
NCT00749723 2018-07-20
HIT-REZ-2005
University Hospital, Bonn
Phase 2/3 Completed
NCT02772107 2016-05-17
Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer
Chinese PLA General Hospital
Phase 2/3 Unknown